



Questionnaire CMC Chemistry Services

When finished, please email reply to: Business Development, Chemic Labs
Email: customerservice@ChemicLabs.com

Today's Date:	
Primary Contact:	
Company or Institution:	
Drug Product/Substance:	
Is a CDA required prior to project initiation?	<input type="checkbox"/> Yes <input type="checkbox"/> No
Services Requested:	<input type="checkbox"/> Method Development <input type="checkbox"/> Method Optimization <input type="checkbox"/> Method Transfer <input type="checkbox"/> Method Validation <input type="checkbox"/> Degradate Product Quantitation <input type="checkbox"/> Chemical and Physical Characterization Studies <input type="checkbox"/> Forced Degradation <input type="checkbox"/> Shelf-life Stability. If so, temperature: <input type="checkbox"/> Accelerated Stability. If so, temperature: <input type="checkbox"/> Other:
Phase of Drug Product/Substance Development, if applicable:	<input type="checkbox"/> Preclinical <input type="checkbox"/> Phase I <input type="checkbox"/> Phase II <input type="checkbox"/> Phase III <input type="checkbox"/> Other
Is the material a controlled substance?	<input type="checkbox"/> Yes <input type="checkbox"/> No If yes: <input type="checkbox"/> Schedule II <input type="checkbox"/> Schedule III <input type="checkbox"/> Schedule IV <input type="checkbox"/> Schedule V
Is the target compound cytotoxic? <i>*If safe bridge III, initial discussion should be scheduled ASAP to determine if project is appropriate fit.</i>	<input type="checkbox"/> Yes <input type="checkbox"/> No If yes: <input type="checkbox"/> Safe bridge I <input type="checkbox"/> Safe bridge II <input type="checkbox"/> Safe bridge III
What agency will this product be regulated by?	<input type="checkbox"/> FDA <input type="checkbox"/> EMEA <input type="checkbox"/> Health Canada <input type="checkbox"/> Other
Desired completion date:	

Questionnaire for CMC Chemistry Services

1. How did you hear about Chemic Laboratories?

- Referral Conference/Meeting Previous Client Internet Search
 Social Media Other

2. Product and Intended Use

- a. Please briefly describe the formulation, including API, and dosing regimen of your Drug Product/Substance:
- b. This product is intended for use in (check all that apply):
- Topical/Oral
 Injectable/Inhalation/Ophthalmic/Other
- c. Therapy Type
- Vaccine
 Cell Therapy
 Antimicrobial
 Oncology
 Other:
- d. Are the following available:
- Placebo formulation
 Qualified reference standards
 Drug substance specific information, if available please briefly describe the following:
- Structure:
 - pKa(s)
 - Solubility
 - Special handling conditions
- e. Please briefly describe storage conditions and/or shelf-life conditions, if known:

3. Container Closure System (Skip if Not Applicable)

- a. Please briefly describe the container closure system, including composition of materials.

Questionnaire for CMC Chemistry Services

- 4. For method development, optimization, transfer, validation, please describe the intent of the methods (e.g., release, stability):**

Assay:

- a. Does a starting point/method exist? Yes No
- b. What are the specifications for this testing?
- c. Does the method need to be stability indicating? Yes No
- d. Is a formal method SOP required at the conclusion of the study: Yes No
- e. Will the method need to be transferred from Chemic to another party? Yes No
- f. Other:

- 5. For services regarding Forced Degradation, Degradate Product Quantitation, and Chemical & Physical Characterization studies, please provide any additional information that you think is relevant:**

- 6. Please provide any other information that may be pertinent.**